$ALKT

Alkami Customers Prevent Over $263 Million in Fraud with BioCatch

Alkami Technology (Nasdaq: ALKT) reported that its customers prevented over $263 million in fraud in 2025 using BioCatch's behavior-based fraud prevention. The partnership helped institutions like Gate City Bank and Raiz Federal Credit Union detect and deter fraudulent activities, with Gate City Bank reporting a 97% account takeover capture rate and $650K in deterred fraud loss over six months.

Original reporting
Published Oct 9, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 2:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alkami Customers Prevent Over $263 Million in Fraud with BioCatch — source image
Decision brief

The 30-second read

$ALKTBullishLow
01

Why it matters

The announcement showcases a successful partnership and quantifies fraud avoided, potentially boosting market perception.

02

Market read

Highlights a notable fraud‑prevention achievement, but limited direct trading impact.

03

What to watch

No details on pricing, adoption rates, or competitive landscape are provided.

Relevance 5/10Novelty 5/10Timing: today

Background

Alkami Technology provides digital banking platforms; BioCatch supplies behavioral analytics for fraud detection.

Company-level read

Ticker impact

$ALKTBullishMedium confidence
Context

Alkami announced its customers prevented over $263M in fraud in 2025 using BioCatch behavior‑based protection.

Expected impact

likely modest upside as the news highlights effective fraud‑prevention capability.

Evidence & confidence

The press release provides new quantitative results, but no direct financial guidance or contract size; impact is limited to perception.

Market effects

demonstrates growing demand for behavioral fraud‑prevention solutions in digital banking.

U.S. banking technology sector may see modest interest.

limited to firms offering similar security platforms.

Counterpoint

The disclosed fraud prevention numbers may not translate into immediate revenue growth for Alkami.

Key entities

  • Alkami Technology, Inc.

    US‑listed digital banking platform provider (NASDAQ: ALKT).

  • BioCatch

    Behavioral analytics firm partnered with Alkami.

Related articles

$ALKTMed

Alkami (ALKT)’s Strategic Review Is Over. What Could Drive the Stock Next?

Alkami Technology (ALKT) decided to remain independent, causing a 20% stock drop. JPMorgan downgraded it to Underweight. The company reports strong recurring revenue growth, expanding margins, and bank expansion. Needham raised its price target to $25. JPMorgan argues ALKT should be valued against Q2 Holdings, warranting a discount. Hedge funds show mixed signals. The focus is now on execution and growth.

$ALKTHigh

Why is Alkami Technology stock plunging today?

Alkami Technology (ALKT) shares fell 18.7% to $14.71 in pre-market trading after its sale process failed to secure a deal, erasing the M&A premium. Activist investor Jana Partners criticized the process, and analysts have cut price targets. The stock is near its 52-week low, with no near-term catalysts. Broader market weakness also contributed to the decline.

$ALKTHighAI 9/10

Alkami (ALKT) Q2 2026 Earnings Call Transcript

Alkami Technology (ALKT) reported Q2 2026 ARR of $511.7 million (+21% YoY) and total revenue of $129.8 million (+15.9% YoY). Non-GAAP gross margin was 63.0% and adjusted EBITDA was $19.4 million. Q3 revenue guidance is $132.7 million to $134.2 million; full-year 2026 revenue guidance is $528 million to $531 million. Bank clients under contract: 54.